Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
China Regenerative Medicine International (HKSE:08158) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
China Regenerative Medicine International's EV-to-EBIT for today is
China Regenerative Medicine International's current Enterprise Value is HK$113.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Regenerative Medicine International's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$16.39 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
China Regenerative Medicine International's EV-to-EBITDA for today is:
China Regenerative Medicine International's current Enterprise Value is HK$113.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Regenerative Medicine International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$16.39 Mil.
China Regenerative Medicine International's current Enterprise Value is HK$113.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Regenerative Medicine International's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$72.06 Mil.
China Regenerative Medicine International's current Enterprise Value is HK$113.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Regenerative Medicine International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$4.10 Mil.
China Regenerative Medicine International's current Enterprise Value is HK$113.72 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. China Regenerative Medicine International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$4.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International Enterprise Value Related Terms
China Regenerative Medicine International Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International Enterprise Value Chart
China Regenerative Medicine International Annual Data
HKSE:08158 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, China Regenerative Medicine International's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International Enterprise Value vs Biotechnology Industry
China Regenerative Medicine International Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$113.72 Mil mean?
China Regenerative Medicine International (HKSE:08158) has a Enterprise Value of HK$113.72 Mil as of Aug. 08, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on China Regenerative Medicine International and its competitors.
Is China Regenerative Medicine International's Enterprise Value too high?
China Regenerative Medicine International's current Enterprise Value is HK$113.72 Mil. Overall, China Regenerative Medicine International has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Enterprise Value compare to VRTX and REGN?
China Regenerative Medicine International's Enterprise Value of HK$113.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on China Regenerative Medicine International and its competitors. China Regenerative Medicine International's current Enterprise Value is HK$113.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
Based on GuruFocus' analysis, China Regenerative Medicine International (HKSE:08158) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.63, compared to a current price of HK$0.23 — trading 63.2% below its estimated fair value. The current Enterprise Value is HK$113.72 Mil. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For China Regenerative Medicine International (HKSE:08158), the current Enterprise Value is HK$113.72 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (HKSE:08158) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of HK$0.23 is trading 63.2% below its estimated GF Value™ of HK$0.63.
GuruFocus considers China Regenerative Medicine International to be Possible Value Trap.
Key valuation signals for HKSE:08158:
Enterprise Value: HK$113.72 Mil
GF Value™: HK$0.63 vs. price of HK$0.23 (63.2% below fair value)
No single metric tells the full story. See the HKSE:08158 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for HKSE:08158
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08158 has been successfully added to your 
